- Home
- NTHI vs NBTX Comparison
NTHI vs NBTX Comparison
Compare NTHI & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTHI | NBTX |
|---|---|---|
| Founded | 2008 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 195.5M | 1.0B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NTHI | NBTX |
|---|---|---|
| Price | $10.19 | $22.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 68.0K | 49.9K |
| Earning Date | 11-14-2025 | 09-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $59,990.00 | ★ $11,930,711.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $136.64 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.20 | $2.82 |
| 52 Week High | $25.00 | $30.35 |
Technical Indicators
Market Signals| Indicator | NTHI | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.54 | 57.57 |
| Support Level | $8.63 | $20.83 |
| Resistance Level | $9.75 | $23.77 |
| Average True Range (ATR) | 0.88 | 0.88 |
| MACD | 0.23 | 0.17 |
| Stochastic Oscillator | 95.59 | 77.16 |
Price Performance
Historical ComparisonAbout NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.